Still, one should not dismiss the possibility of profit. Not entirely. It’s a grim business, this chasing of dividends, like scavenging for crumbs beneath the table of pharmaceutical giants. But crumbs, when accumulated, can sustain a man. Or at least, a portfolio.
They increased their holding in the fourth quarter. That’s the official story. The numbers have gone up, of course. A hefty 120% over the year. Which, in my experience, usually means someone, somewhere, is trying very hard to convince you something is worth more than it is. The fund’s position increased by $60.94 million – a blend of actual investment and, let’s be honest, a bit of market froth. It’s like watching a magician; you know there’s a trick, but you’re still momentarily impressed by the disappearing rabbit.
The filing with the SEC confirms the transaction – $43.14 million sunk into a company down nearly 38% in a year. A bold move, or a desperate one? Newtyn now holds 4.53% of Integer, a stake built on the ruins of past optimism. One wonders if they consulted the assembly line workers, the ones who actually make the devices, before committing such a sum.
Transaction value is calculated based on the SEC Form 4 weighted average purchase price of $71.87; post-transaction value is based on the February 3, 2026 market close price of $71.87.
If you asked me where to put it, well, I’d say look at the companies that seem to know what everyone else is thinking before they do. Two of them, in particular. They’re busy building the future, or at least a very convincing imitation of one. Artificial intelligence. Sounds like science fiction, doesn’t it? It’s just business now.
The fine print says it was tied to an option exercise. A neat little dance where Willett cashed in some paper, then immediately sold the resulting shares. The weighted average price came in around $59.50. The market closed at $58.79 that day. A difference so small, it could have been lost in the static. It smelled less like a conviction, more like a pre-arranged agreement.
Which brings us to Rocket Lab. Rocket Lab (RKLB 7.50%). They’re trying, I’ll give them that. They’re launching things. Smaller things, admittedly. But launching. And they’ve managed to do it without, you know, exploding. Most of the time. It’s a start. They’ve grown revenue, they say, by 900% in five years. Okay. Fine. But is that good growth? Is it the kind of growth that justifies… well, anything?
Walmart’s resilience in the face of sector-wide headwinds affecting consumer staples is acknowledged. However, the current forward price-to-earnings (P/E) ratio of 45.2 appears extended, particularly when juxtaposed with the S&P 500 average of 23.6. The premium assigned to Walmart exceeds that of the so-called “Magnificent Seven,” with the notable exception of Tesla. This suggests the market has already priced in a substantial degree of future growth, leaving limited margin for positive surprise.
They say a man is judged by his deeds, and Novartis has been steadily doin’ alright by its shareholders. It’s not a stock to set your hair on fire, mind you, but a fella lookin’ for a bit of peace of mind, a place to park his money where it’ll grow slow and steady, might just find it here.
The weighted average price, according to the Form 4, hovered around $54.97. A sum, naturally, that means little to those who dwell in the ethereal realms of algorithms, but much to those who calculate their lives in fractions of a cent.